For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...
Parents on MSN6mon
What Does It Mean to Have a Frank Breech Baby?The presenting part, which is the part of the baby's body that is born first in a vaginal delivery, is usually the baby's ...
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx.
Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...
Oncternal Therapeutics (NASDAQ:ONCT) versus Vertex Pharmaceuticals (NASDAQ:VRTX) Head to Head Survey
16.0% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.2% of Oncternal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback